Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
grade A 14.94 0.20% 0.03
CORT closed up 0.2 percent on Friday, January 18, 2019, on 75 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CORT trend table...

Date Alert Name Type % Chg
Jan 18 200 DMA Support Bullish 0.00%
Jan 18 Inside Day Range Contraction 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Stochastic Sell Signal Bearish 0.20%
Jan 17 200 DMA Support Bullish 0.20%
Jan 17 Overbought Stochastic Strength 0.20%
Jan 16 Overbought Stochastic Strength -3.30%
Jan 16 Upper Bollinger Band Touch Strength -3.30%
Jan 15 Pocket Pivot Bullish Swing Setup -4.90%
Jan 15 Above Upper BB Strength -4.90%

Older signals for CORT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Is CORT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.96
52 Week Low 11.21
Average Volume 1,539,008
200-Day Moving Average 14.826
50-Day Moving Average 13.7915
20-Day Moving Average 13.805
10-Day Moving Average 14.559
Average True Range 0.8168
ADX 18.16
+DI 30.611
-DI 20.2531
Chandelier Exit (Long, 3 ATRs ) 13.6296
Chandelier Exit (Short, 3 ATRs ) 14.1504
Upper Bollinger Band 15.7891
Lower Bollinger Band 11.8209
Percent B (%b) 0.79
BandWidth 28.744658
MACD Line 0.371
MACD Signal Line 0.2156
MACD Histogram 0.1554
Fundamentals Value
Market Cap 1.69 Billion
Num Shares 113 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 74.70
Price-to-Sales 19.04
Price-to-Book 31.30
PEG Ratio 0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.59
Resistance 3 (R3) 15.60 15.40 15.48
Resistance 2 (R2) 15.40 15.24 15.39 15.44
Resistance 1 (R1) 15.17 15.13 15.07 15.16 15.41
Pivot Point 14.97 14.97 14.92 14.96 14.97
Support 1 (S1) 14.74 14.81 14.64 14.73 14.47
Support 2 (S2) 14.54 14.70 14.53 14.44
Support 3 (S3) 14.31 14.54 14.40
Support 4 (S4) 14.30